Holen Sie sich die Stockscreener-App
22.88
1.00%
-0.205
Schlusskurs vom Vortag:
$23.08
Offen:
$23.15
24-Stunden-Volumen:
253.18K
Relative Volume:
0.22
Marktkapitalisierung:
$1.07B
Einnahmen:
$82.71M
Nettoeinkommen (Verlust:
$-102.24M
KGV:
-6.233
EPS:
-3.67
Netto-Cashflow:
$-76.57M
1W Leistung:
-6.28%
1M Leistung:
-1.68%
6M Leistung:
+225.50%
1J Leistung:
+87.76%
1-Tages-Spanne:
$22.87
$23.56
1-Wochen-Bereich:
$22.51
$25.83
52-Wochen-Spanne:
$3.42
$30.00
Urogen Pharma Ltd Stock (URGN) Company Profile
Firmenname
Urogen Pharma Ltd
Sektor
Branche
Telefon
972 9 770 7601
Adresse
9 HA'TA'ASIYA ST, RA'ANANA
Vergleichen Sie URGN mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
URGN
Urogen Pharma Ltd
|
22.88 | 1.08B | 82.71M | -102.24M | -76.57M | -3.67 |
|
VRTX
Vertex Pharmaceuticals Inc
|
441.55 | 112.15B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
699.37 | 73.91B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
417.50 | 56.81B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ARGX
Argen X Se Adr
|
893.54 | 55.46B | 3.06B | 1.28B | 447.35M | 19.67 |
|
INSM
Insmed Inc
|
194.04 | 41.92B | 447.02M | -1.18B | -906.14M | -6.1812 |
Urogen Pharma Ltd Stock (URGN) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-08-19 | Eingeleitet | Piper Sandler | Overweight |
| 2025-06-16 | Hochstufung | H.C. Wainwright | Neutral → Buy |
| 2025-05-22 | Herabstufung | H.C. Wainwright | Buy → Neutral |
| 2025-04-16 | Eingeleitet | Scotiabank | Sector Outperform |
| 2025-02-19 | Fortgesetzt | Ladenburg Thalmann | Buy |
| 2024-08-22 | Eingeleitet | Guggenheim | Buy |
| 2023-02-08 | Herabstufung | Jefferies | Buy → Hold |
| 2022-04-27 | Eingeleitet | Berenberg | Buy |
| 2020-04-16 | Bestätigt | H.C. Wainwright | Buy |
| 2020-04-13 | Bestätigt | H.C. Wainwright | Buy |
| 2020-01-09 | Eingeleitet | National Securities | Neutral |
| 2019-05-30 | Eingeleitet | JP Morgan | Neutral |
| 2019-05-29 | Eingeleitet | Goldman | Neutral |
| 2019-01-29 | Eingeleitet | H.C. Wainwright | Buy |
| 2018-11-08 | Fortgesetzt | Jefferies | Buy |
| 2018-04-04 | Hochstufung | Raymond James | Mkt Perform → Outperform |
| 2018-01-02 | Eingeleitet | Ladenburg Thalmann | Buy |
| 2017-11-15 | Bestätigt | Oppenheimer | Outperform |
| 2017-11-15 | Herabstufung | Raymond James | Outperform → Mkt Perform |
Alle ansehen
Urogen Pharma Ltd Aktie (URGN) Neueste Nachrichten
Urogen Pharma milestone: first patient treated with new cancer medication - Traders Union
Walleye Capital LLC Takes Position in Urogen Pharma $URGN - MarketBeat
Bronstein, Gewirtz & Grossman, LLC Is Investigating UroGen Pharma - The National Law Review
UroGen Pharma (URGN) Issues Stock Units to New Employees - GuruFocus
UroGen Pharma Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - The Manila Times
UroGen Pharma (NASDAQ: URGN) issues 32,500 inducement RSUs to 14 new employees - Stock Titan
UroGen Pharma Ltd. (NASDAQ:URGN) Stock Rockets 26% As Investors Are Less Pessimistic Than Expected - simplywall.st
Panagora Asset Management Inc. Acquires 168,908 Shares of Urogen Pharma $URGN - MarketBeat
Is UroGen Pharma Ltd. (UR8) stock prepared for digital transition2025 Biggest Moves & Free Reliable Trade Execution Plans - Newser
What margin trends mean for UroGen Pharma Ltd. stockJuly 2025 Decliners & Fast Gaining Stock Strategy Reports - Newser
Why UroGen Pharma Ltd. (UR8) stock signals breakout potentialJuly 2025 Fed Impact & Fast Gain Swing Trade Alerts - Newser
Urogen Pharma (NASDAQ:URGN) Trading Down 6.1%What's Next? - MarketBeat
UroGen Pharma Ltd (URGN) Stock Price, Trades & News - GuruFocus
Muscle Invasive Bladder Cancer Market to Reach New Heights - openPR.com
Can UroGen Pharma Ltd. (UR8) stock test all time highs2025 Price Targets & Free Verified High Yield Trade Plans - Newser
UroGen Pharma (URGN) Stock Analysis Report | Ratings, Financials & Performance - Benzinga
Piper Sandler Healthcare Conference - marketscreener.com
Discipline and Rules-Based Execution in URGN Response - news.stocktradersdaily.com
Is UroGen Pharma Ltd. stock oversold or undervaluedJuly 2025 Closing Moves & AI Powered Buy and Sell Recommendations - BỘ NỘI VỤ
Bronstein, Gewirtz & Grossman, LLC Initiates an Investigation int - The National Law Review
Entropy Technologies LP Buys New Shares in Urogen Pharma $URGN - MarketBeat
UroGen Reports Third Quarter 2025 Financial Results as ZUSDURI™ Launch Gains Momentum - ADVFN
Urogen Pharma (NASDAQ:URGN) Sets New 12-Month HighHere's Why - MarketBeat
What analysts say about UroGen Pharma Ltd stockEarnings Revision Updates & Free Tremendous Return On Equity - earlytimes.in
UroGen Pharma Ltd (UR8.DU) stock price, news, quote and history - Yahoo Finance UK
UroGen Pharma Ltd. (NASDAQ:URGN) Q1 2025 Earnings Call Transcript - MSN
UroGen Pharma: Strong Potential As Zusduri Commercialization Accelerates - Seeking Alpha
UroGen Pharma to Present at the Piper Sandler 37th Annual Healthcare Conference - The Manila Times
Will UroGen Pharma Ltd. stock attract more institutional investors2025 Sector Review & Fast Exit/Entry Strategy Plans - newser.com
Insider Selling: Urogen Pharma (NASDAQ:URGN) Insider Sells 10,000 Shares of Stock - MarketBeat
UroGen Pharma CMO Schoenberg sells $250,000 in shares By Investing.com - Investing.com South Africa
UroGen Pharma CMO Schoenberg sells $250,000 in shares - Investing.com
[Form 4] UroGen Pharma Ltd. Insider Trading Activity - Stock Titan
Does UroGen Pharma Ltd. stock trade at a discount to peersQuarterly Performance Summary & High Accuracy Swing Entry Alerts - newser.com
Will UroGen Pharma Ltd. (UR8) stock sustain dividend payoutsOptions Play & Precise Trade Entry Recommendations - newser.com
Is UroGen Pharma Ltd. (UR8) stock undervalued after correction2025 Technical Patterns & Real-Time Volume Analysis Alerts - newser.com
Urogen Pharma Ltd stock hits 52-week high at 25.2 USD - Investing.com Nigeria
Will UroGen Pharma Ltd. (UR8) stock gain from green policiesQuarterly Earnings Summary & Reliable Intraday Trade Alerts - newser.com
Why global investors buy UroGen Pharma Ltd. (UR8) stockWeekly Market Summary & Safe Capital Allocation Plans - newser.com
Is UroGen Pharma Ltd. (UR8) stock good for long term investing2025 EndofYear Setup & Safe Entry Zone Tips - newser.com
Finanzdaten der Urogen Pharma Ltd-Aktie (URGN)
Umsatz
Nettogewinn
Free Cashflow
ENV
1.06%
0.06%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):